Dustin Samples

Cancer Nursing Today nonprod

In an abstract presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO), Houston, Texas, researchers from the Dana Farber Cancer Institute, Boston, Massachusetts, and Massachusetts General Hospital, Boston, shared the results of 20 years of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in patients with T-cell prolymphocytic leukemia (T-PLL).Data from 35 patients treated with allo-HSCT at either institution from 2002-2022 were collected and analyzed for several outcomes. The median patient age was 61 at the time of transplant.Most patients underwent only 1 transplant, and none had more than 2. Most (66%) received donor cells from an unrelated matched donor, and 74% had preconditioning with alemtuzumab. Nearly one-third received graft-versus-host disease (GVHD) prophylaxis with methotrexate, sirolimus, and tacrolimus.At a median follow-up of 60.8 months, 46% and 37% had acute and chronic GVHD, respectively. Most patients with acute GVHD were grade II (56%) and none were grade IV. Chronic GVHD was mild for 69% of patients who developed it, and there were no severe cases.Median overall survival in this study was 24 months, and the most common cause of death was disease progression.Regarding mortality rates, the authors noted, &ldquo;At 72 months, the probability of non-relapse mortality in the patients with vs without GVHD was 0.44 (0.18-0.71) vs 0.7 (0.3-1.11), and the transplant-related mortality (TRM) was 0.19 (0.02-0.37) vs 0.08 (0-0.23).&rdquo;These results led the authors to conclude that T-PLL outcomes &ldquo;remain dismal&rdquo; despite transplantation and that novel therapies are needed for this rare disease.ReferenceMerrill M, Redd R, Singh S, et al. The Outcomes of Patients With T-Cell Prolymphocytic Leukemia After Allogenic Stem Cell Transplant: A Multicenter Retrospective Study. Abstract TCL-423. Presented at the 11th Annual Meeting of the Society of Hematologic Oncology; September 6-9, 2023; Houston, Texas.

GVHD and Mortality Outcomes for T-PLL After Allogeneic HSCT

Conferences

Despite advances in understanding GVHD, outcomes remain poor for patients with T-PLL.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe